Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-1801
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients ; volume:5 ; number:1 ; day:17 ; month:8 ; year:2016 ; pages:1-9 ; date:12.2016
SpringerPlus ; 5, Heft 1 (17.8.2016), 1-9, 12.2016
- Urheber
-
Hallinen, Taru
- Beteiligte Personen und Organisationen
-
Soini, Erkki J.
Linna, Miika
Saarni, Samuli I.
SpringerLink (Online service)
- DOI
-
10.1186/s40064-016-3024-5
- URN
-
urn:nbn:de:1111-201609154020
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hallinen, Taru
- Soini, Erkki J.
- Linna, Miika
- Saarni, Samuli I.
- SpringerLink (Online service)
Ähnliche Objekte (12)
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
Initial apixaban dosing in patients with atrial fibrillation
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study
Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings
The use of warfarin in veterans with atrial fibrillation
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin – propensity score matching study
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
Initial apixaban dosing in patients with atrial fibrillation
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study
Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings
The use of warfarin in veterans with atrial fibrillation
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin – propensity score matching study
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
Initial apixaban dosing in patients with atrial fibrillation
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study
Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings
The use of warfarin in veterans with atrial fibrillation
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease